(Q34980952)

5 August 2017

1 reference

title

Bortezomib: a review of its use in patients with multiple myeloma (English)

1 reference

5 August 2017

1

Monique P Curran

1 reference

5 August 2017

2

Kate McKeage

1 reference

5 August 2017

publication date

1 January 2009

1 reference

5 August 2017

1 reference

5 August 2017

volume

69

1 reference

5 August 2017

issue

7

1 reference

5 August 2017

page(s)

859-888

1 reference

Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells

5 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200969070-00006

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200969070-00006

The role of Dickkopf-1 in bone development, homeostasis, and disease

21 January 2018

1 reference

12 December 2020

Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites

1 reference

12 December 2020

Lenalidomide in myelodysplastic syndrome and multiple myeloma

1 reference

12 December 2020

A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma

1 reference

12 December 2020

Myeloma bone disease and proteasome inhibition therapies.

1 reference

12 December 2020

The potential of proteasome inhibitors in cancer therapy

1 reference

12 December 2020

Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

1 reference

12 December 2020

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

12 December 2020

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

12 December 2020

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines

1 reference

12 December 2020

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

12 December 2020

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

1 reference

12 December 2020

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

12 December 2020

1 reference

12 December 2020

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

12 December 2020

Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes

1 reference

12 December 2020

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

1 reference

12 December 2020

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

1 reference

12 December 2020

Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta

1 reference

12 December 2020

Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A

1 reference

12 December 2020

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

12 December 2020

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

1 reference

12 December 2020

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

12 December 2020

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

12 December 2020

A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B

1 reference

12 December 2020

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

1 reference

12 December 2020

Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21

1 reference

12 December 2020

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma

1 reference

12 December 2020

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

1 reference

12 December 2020

The proteasome inhibitor PS-341 in cancer therapy.

1 reference

12 December 2020

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

1 reference

12 December 2020

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

1 reference

12 December 2020

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

1 reference

12 December 2020

The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

1 reference

12 December 2020

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

1 reference

12 December 2020

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

1 reference

12 December 2020

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

1 reference

12 December 2020

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

1 reference

12 December 2020

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.

1 reference

12 December 2020

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

12 December 2020

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

1 reference

12 December 2020

Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma

1 reference

12 December 2020

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

1 reference

12 December 2020

Pathogenesis and treatment of renal failure in multiple myeloma

1 reference

12 December 2020

In vivo ubiquitination and proteasome-mediated degradation of p53(1)

1 reference

12 December 2020

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

12 December 2020

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

12 December 2020

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

12 December 2020

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

12 December 2020

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

1 reference

12 December 2020

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

1 reference

12 December 2020

mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway

1 reference

12 December 2020

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

12 December 2020

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

1 reference

12 December 2020

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

1 reference

12 December 2020

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

12 December 2020

Cancer statistics, 2008

1 reference

12 December 2020

Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease

1 reference

12 December 2020

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

12 December 2020

Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

1 reference

12 December 2020

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

1 reference

12 December 2020

International uniform response criteria for multiple myeloma.

1 reference

12 December 2020

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

1 reference

12 December 2020

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

1 reference

12 December 2020

An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma

1 reference

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

12 December 2020

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

1 reference

12 December 2020

Bortezomib inhibits human osteoclastogenesis.

1 reference

12 December 2020

Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.

1 reference

12 December 2020

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

1 reference

12 December 2020

Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.

1 reference

12 December 2020

10.2165/00003495-200969070-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1025828980

0 references

1 reference